The approval last week of the first RNAi therapy was a watershed moment for the advancement of medicine. After years of waiting, finally, the hope for the therapeutic application of RNAi platforms has been realized.
This is only the beginning, and now a number of biotechs have the opportunity to ride the wave of confidence and seek support for their own RNAi candidates. Sirnaomics is looking to the oncology space, hoping to find another route in to attacking an aggressive and poorly-treated form of cancer.
Sirnaomics’ founder and CEO Patrick Lu, Ph.D., said the patisiran approval “validates the RNAi class of therapeutics and it is our belief that the industry will see great enthusiasm and expanded discovery and development of novel RNAi therapeutics for many disease applications.”